Generic and innovative drugs markets in Central and Eastern Europe 2009

• Bulgaria,
• Czech Republic,
• Hungary,
• Poland,
• Romania,
• Russia,
• Slovakia,
• Ukraine.

Request sample pages/interactive screenshare

1. Report methodology

2. Executive summary

3. Characteristics of generic and innovative drug markets in CEE countries

• Comparative analysis
• General characteristics of the market
• Important mergers and acquisitions influencing the CEE market
• Market value between 2007 and 2011
• Share of generic and innovative drugs as a proportion of overall market
• Russia
• Main trends and events on generic and innovative drug market
• Market size
• Share of pharmaceutical market
• Market forecasts for 2009-2011
• Consumer behaviour pertaining to innovative and generic medicines
• Attitudes of doctors and pharmacists toward generic and innovative drugs
• Frequency of prescribing and demand for generic and innovative drugs
• Poland
• Main trends and events on generic and innovative drug market
• Market size
• Share of pharmaceutical market
• Market forecasts for 2009-2011
• Attitudes toward generic and innovative drugs
• Poles’ opinion about generic drugs
• Poles’ opinions about innovative drugs
• Attitudes of doctors toward pharmaceutical companies
• Czech Republic
• Main trends and events on generic and innovative drug market
• Market size
• Share of pharmaceutical market
• Market forecasts for 2009-2011
• Romania
• Main trends and events on generic and innovative drug market
• Market size
• Share of pharmaceutical market
• Market forecasts for 2009-2011
• Hungary
• Main trends and events on generic and innovative drug market
• Market size
• Share of pharmaceutical market
• Market forecasts for 2009-2011
• Consumer behaviour pertaining to innovative and generic medicines
• Ukraine
• Main trends and events on generic and innovative drug market
• Market size
• Share of pharmaceutical market
• Market forecasts for 2009-2011
• Consumer behaviour pertaining to innovative and generic medicines
• Doctors’ knowledge of medicine prices
• Optimal drug prices
• Sources of knowledge of medicine prices
• Generic substitution
• Slovakia
• Main trends and events on generic and innovative drug market
• Market size
• Share of pharmaceutical market
• Market forecasts for 2009-2011
• Consumer behaviour pertaining to innovative and generic medicines
• Understanding of the term “generic”
• Attitudes of patients toward the use of generics
• Interest in generics and generic substitutes
• Attitudes of doctors and pharmacists toward generics
• Bulgaria
• Main trends and events on generic and innovative drug market
• Market size
• Share of pharmaceutical market
• Market forecasts for 2009-2011
• Consumer behaviour pertaining to innovative and generic medicines
• Cost of medicines
• Attitudes toward state drug policy
• Doctors' attitudes toward generic and innovative drugs

4. Best selling drugs in Central and Eastern Europe

• Russia
• Best selling drugs
• Drug patent expiry and data exclusivity periods
• Poland
• Best selling drugs
• Drug patent expiry and data exclusivity periods
• Czech Republic
• Best selling drugs
• Drug patent expiry and data exclusivity periods
• Romania
• Best selling drugs
• Drug patent expiry and data exclusivity periods
• Hungary
• Best selling drugs
• Drug patent expiry and data exclusivity periods
• Ukraine
• Best selling drugs
• Drug patent expiry and data exclusivity periods
• Slovakia
• Drug patent expiry and data exclusivity periods
• Bulgaria
• Drug patent expiry and data exclusivity periods
• Comparative analysis of drug patent expiry and data exclusivity periods in CEE

5. Counterfeit products

• Russia
• Poland
• Czech Republic
• Romania
• Hungary
• Ukraine
• Slovakia
• Bulgaria

6. Reimbursement and pricing policies in Central and Eastern Europe

• Russia
• Pricing policies
• Reimbursement policies
• Poland
• Pricing policies
• Reimbursement policies
• Czech Republic
• Pricing policies
• Reimbursement policies
• Romania
• Pricing policies
• Reimbursement policies
• Hungary
• Pricing policies
• Reimbursement policies
• Ukraine
• Pricing policies
• Reimbursement policies
• Slovakia
• Pricing policies
• Reimbursement policies
• Bulgaria
• Pricing policies
• Reimbursement policies

7. Key manufacturers

• Profiles of selected leading innovative drug manufacturers in CEE
• Profiles of selected leading generic drug manufacturers in CEE
• Key players in selected CEE countries
• Russia
• Poland
• Czech Republic
• Hungary
• Romania
• Ukraine
• Bulgaria

8. List of graphs

9. List of tables

10. About PMR

11. Contact PMR

List of graphs

1. Value (€ bn) and y-o-y growth of the generics drug market in Central and Eastern Europe, 2007-2011
2. Value (€ bn) and y-o-y growth of the innovative drug market in Central and Eastern Europe, 2007-2011
3. CAGR for generics drug markets in the countries analysed, 2009-2011
4. CAGR for innovative drug markets in the countries analysed, 2009-2011
5. Percentage of top 20 global companies sales exposed to generic competition, before and after 2012
6. Number of molecules available to patients at reference date in CEE countries in comparison with the countries with the highest scores, 2007
7. The proportion of total sales of cancer drugs in selected CEE countries analysed, by date of launch, 2007
8. Value (€ bn) and y-o-y growth of the generics drug market in Central and Eastern Europe, 2007-2011
9. Value (€ bn) and y-o-y growth of the innovative drug market in Central and Eastern Europe, 2007-2011
10. Share of generic and innovative drugs as a proportion of the overall pharmaceutical market of Central and Eastern Europe, 2008-2011
11. Share of generic and innovative drugs as a proportion of the overall pharmaceutical market in the countries analysed, 2008
12. Market value ($ m) of generic and innovative medicines in Russia, 2005-2008
13. Share of generic and innovative drugs as a proportion of overall pharmaceutical market in Russia, by value, 2007
14. Share of high-tech pharmaceutical substances as proportion of total market value in Russia, 2009
15. Share of foreign innovative substances as a proportion of reimbursement and hospital purchases in Russia, by value, 2007
16. Share of foreign innovative substances as a proportion of reimbursement and hospital purchases in Russia, by volume, 2007
17. Market value (€ m) and y-o-y growth of the Russian generics drug market, 2007-2011
18. Market value (€ m) and y-o-y growth of the Russian innovative drug market, 2007-2011
19. Definitions of “innovative drug” provided by pharmacists in Russia, 2008
20. Definitions of “innovative drug” provided by doctors in Russia, 2008
21. Definitions of “branded generic” provided by pharmacists in Russia, 2008
22. Definitions of “branded generic” provided by doctors in Russia, 2008
23. Opinions of Russian doctors and pharmacists on innovative drugs, 2008
24. Incidence of often prescribing innovative and generic drugs among Russian cardiologists and physicians, 2008
25. Which kinds of drugs are most in demand at your pharmacy?, Russia, 2008
26. Market value (PLN m) of generic and innovative medicines in Poland, 2004-2007
27. Market volume (million of units) of generic and innovative medicines in Poland, 2004-2007
28. Share of generic and innovative drugs as a proportion of overall pharmaceutical market in Poland, by value, Q3 2007 - Q3 2008
29. Share of generic and innovative drugs as a proportion of overall pharmaceutical market in Poland, by volume, Q3 2007 - Q3 2008
30. Share of generic and innovative drugs as a proportion of Rx pharmaceutical market in Poland, by value, 2004-2007
31. Share of generic and innovative drugs as a proportion of Rx pharmaceutical market in Poland, by volume, 2004-2007
32. Share of generic and innovative drugs as a proportion of reimbursed drug market in Poland, by value, Q1 2002-Q3 2008
33. Market value (€ m) and y-o-y growth of the Polish generics drug market, 2007-2011
34. Market value (€ m) and y-o-y growth of the Polish innovative drug market, 2007-2011
35. Doctors informing Polish patients about cheaper equivalents of expensive drugs, 2001, 2003, 2005 and 2007
36. Poles’ opinions on Polish equivalents of foreign drugs, 2001, 2003, 2005 and 2007
37. Respondents’ opinions about generic drugs in Poland and other European countries, 2008
38. Attitudes of Poles toward innovative drugs and treatment, 2008
39. Ethical forms of meetings with pharmaceutical representatives in Poland (% of respondents), 2008
40. The best form of contact with a pharmaceutical representative in Poland (% of respondents), 2009
41. Proposed reduction in prices of medicines in the Czech Republic, 2009
42. Market value (CZK bn) of generic and innovative medicines in the Czech Republic, 2004-2008
43. Sales of orphan drugs in the Czech Republic, by value (CZK m), 2005-H1 2009
44. Sales of orphan drugs in the Czech Republic, by volume, 2005-H1 2009
45. Share of generic and innovative drugs as a proportion of overall pharmaceutical market in the Czech Republic, by value, 2001-2007
46. Share of generic and innovative drugs as a proportion of overall pharmaceutical market in the Czech Republic, by volume, 2001-2007
47. Market value (€ m) and y-o-y growth of the Czech generics drug market, 2004-2011
48. Market value (€ m) and y-o-y growth of the Czech innovative drug market, 2004-2011
49. Estimated share of generic and innovative drugs as a proportion of overall pharmaceutical market in Romania, by value, 2008
50. Estimated share of generic and innovative drugs as a proportion of overall pharmaceutical market in Romania, by volume, H1 2009
51. Market value (€ m) and y-o-y change of the Romanian generics drug market, 2007-2011
52. Market value (€ m) and y-o-y change of the Romanian innovative drug market, 2007-2011
53. Estimated share of generic and innovative drugs as a proportion of pharmaceutical market in Hungary, by value, 2008
54. Respondent’s opinion about generic drugs in Hungary and other European countries, 2006
55. Market value (UAH bn) and number of packages sold (m) of generic and innovative medicines in Ukraine, January-July 2009
56. Average price of generic and innovative medicines in the Ukrainian retail market (UAH), January 2006-August 2008
57. Share of generic and innovative drugs as a proportion of retail pharmaceutical market in Ukraine, by value, January 2007-July 2009
58. Share of generic and innovative drugs as a proportion of retail pharmaceutical market in Ukraine, by volume, January 2007-July 2009
59. Share of generic and innovative drugs as a proportion of hospital market in Ukraine, by value, H1 2007 and H1 2008
60. Share of generic and innovative drugs as a proportion of hospital market in Ukraine, by volume, H1 2007 and H1 2008
61. Market value (€ m) and y-o-y growth of the Ukrainian generics drug market, 2007-2011
62. Market value (€ m) and y-o-y growth of the Ukrainian innovative drug market, 2007-2011
63. Doctors’ knowledge of the prices of Rx medicines which they prescribe in Ukraine, 2009
64. Price breakdown of generic and original drug market in Ukraine, in the opinion of doctors , 2009
65. Sources of information on drug prices for physicians in Ukraine, 2009
66. Estimated market value (SKK m) of generic and innovative medicines in Slovakia, 2007-2008
67. Share of generic and innovative drugs as a proportion of overall pharmaceutical market in Slovakia, by value, 2008
68. Market value (€ m) and y-o-y growth of the Slovak generics drug market, 2005-2011
69. Market value (€ m) and y-o-y growth of the Slovak innovative drug market, 2005-2011
70. Understanding of the term “generic medicinal product” in Slovakia, 2007
71. Attitudes of patients toward the use of generic drugs in Slovakia, 2007
72. Attitudes of patients toward generic substitutes in Slovakia, 2007
73. Market value (BGN m) and number of packages sold (m) of generic and innovative medicines in Bulgaria, 2007-2008
74. Share of generic and innovative drugs as a proportion of overall pharmaceutical market in Bulgaria, by value and volume, by INN, 2008
75. Share of generic and innovative drugs as a proportion of overall pharmaceutical market in Bulgaria, by value, by company image, 2006-2008
76. Market value (€ m) and y-o-y growth of the Bulgarian generics drug market, 2007-2011
77. Market value (€ m) and y-o-y growth of the Bulgarian innovative drug market, 2007-2011
78. Amount of money patients had to spend on drugs used in hospital treatment in Bulgaria, 2008
79. Source of funding of drugs used in home treatment in Bulgaria, 2008
80. Satisfaction with state drug policy in Bulgaria, 2008
81. Opinions about state drug policy in Bulgaria, 2008
82. Doctors’ opinions on generic and innovative drugs in Bulgaria, 2007
83. The difference between the cost of an imported drug and its final consumer price in Russia, Q2 2009
84. Average retail markup for drugs in selected regions of Russia, Q1 2009
85. Expenses within the Federal Reimbursement Programme in Russia (RUB bn), 2008-2009
86. The share of local and imported drugs as a proportion of the Russian pharmaceutical market, by value, H1 2008 and H1 2009
87. Pricing and reimbursement process in Russia, 2009
88. Average pharmacy margin for non-reimbursed products in Poland, January 2008-June 2009
89. Price build-up of reimbursed medicines in Poland, pharmacy market, 2009
90. Distribution of medicines in the Czech Republic in accordance with price of medicine, by volume and by value, Q2 2009
91. Share of the cheapest and the most expensive drugs as a proportion of the overall Rx market in Romania, 2008 and Q2 2009
92. Gross average retail markup for drugs in Romania, 2009
93. Average retail markup for generic and innovative drugs in Ukraine, January 2006-August 2008
94. Example calculation of the maximum price of an Rx medicine in Slovakia, 2009
95. AstraZeneca spending on research and development ($ m), y-o-y change and its share as a proportion of the company’s revenues, 2004-2008
96. Bayer HealthCare sales structure, by division, 2008
97. Bayer HealthCare spending on research and development (€ m), y-o-y change and its share as a proportion of the company’s net sales, 2004-2008
98. GlaxoSmithKline spending on research and development (£ m), y-o-y change and its share as a proportion of the company’s turnover, 2001-2008
99. Novartis group sales structure, 2008
100. Novartis Pharmaceuticals spending on research and development ($ m), y-o-y increase and its share as a proportion of the company’s net sales, 2004-2008
101. Pfizer spending on research and development ($ m), y-o-y change and its share as a proportion of the company’s revenues, 2004-2008
102. Roche sales structure, by division, 2008
103. Sales of key Roche products in Romania, H1 2009
104. Roche Pharmaceuticals spending on research and development (CHF m), y-o-y increase and its share as a proportion of the company’s sales, 2004-2008
105. Sanofi-Aventis ownership structure, June 2009
106. Sanofi-Aventis sales structure in Russia, 2008
107. Sanofi-Aventis spending on research and development (€ m), y-o-y increase and its share as a proportion of the company’s net sales, 2004-2008
108. Sales of key Servier products in Romania, H1 2009
109. Actavis sales revenues structure, by region, 2008
110. Antibiotice ownership structure, September 2009
111. Revenues (RON m) and y-o-y change of Antibiotice, 2002-2008
112. Dr. Reddy’s ownership structure, March 2009
113. Sales revenues ($ m) from generic drug sales and y-o-y growth of Dr. Reddy’s in Russia, FY 05 - FY 09
114. Dr. Reddy’s spending on research and development (RS m), y-o-y change and its share in company’s revenues, FY 01-09
115. Egis ownership structure, June 2009
116. Egis sales in CEE countries, Q1-Q3 2008/2009
117. Sales revenues ($ m) and y-o-y change of Egis in the CEE countries analysed, Q1-Q3 2008/2009
118. Egis spending on research and development (HUF m), y-o-y increase and its share in company’s net sales, FY 2000/2001-2008/2009
119. Gedeon Richter ownership structure, June 2009
120. Gedeon Richter sales in CEE countries, H1 2009
121. Sales turnover (€ m) of Gedeon Richter in the CEE countries analysed, 2008 and H1 2009
122. Share of original drugs as a proportion of Gedeon Richter’s total sales, 2008
123. Share of original drugs as a proportion of Gedeon Richter’s total sales, 2000-2008
124. Gedeon Richter spending on research and development (HUF m), y-o-y increase and its share as a proportion of the company’s sales, 2000-H1 2009
125. Krka ownership structure, June 2009
126. Krka sales in CEE countries, H1 2009
127. Sales revenues (€ m) and y-o-y change of Krka in the CEE countries analysed, H1 2009
128. Number of new marketing authorisations obtained by Krka in Central European region, 2004-2008
129. Krka spending on research and development (€ m), y-o-y increase and its share in company’s sales revenues, 2003-H1 2009
130. Pharmstandard ownership structure, H1 2009
131. Sales value (RUB bn) and y-o-y growth of Pharmstandard in Russia, 2004-H1 2009
132. Pharmstandard sales structure, by branded and non-branded OTC and Rx drugs, H1 2009
133. Ranbaxy ownership structure, 2008
134. Sales value ($ m) and y-o-y change of Ranbaxy on its key CEE markets, 2008 and H1 2009
135. Sales value ($ m) and y-o-y change of Ranbaxy in Romania, 2004-H1 2009
136. Ranbaxy spending on research and development (RS m), y-o-y change and its share as a proportion of the company’s revenues, 2004-2008
137. Sandoz sales growth on selected CEE markets, 2007
138. Sanzoz’s spending on research and development ($ m), y-o-y increase and its share in company’s net sales, 2005-2008
139. Stada sales in CEE countries, H1 2009
140. Sales value (€ m) of Stada in the analysed CEE countries, 2008 and H1 2009
141. Sales (€ m) of generic and branded drugs of Stada in selected CEE countries analysed, 2008
142. Sales (€ m) of generic and branded drugs of Stada in the CEE countries analysed, H1 2009
143. Stada spending on research and development (€ m), y-o-y increase and its share in company’s sales, 2001-2008
144. Teva global sales, by region, Q2 2009
145. Sales revenues (HRK m) and y-o-y change of Pliva, 2006-H1 2009
146. Teva’s spending on research and development ($ m), y-o-y increase and its share as a proportion of the company’s revenues, 2001-2008
147. Zentiva sales in CEE countries, 2008
148. Net pharmaceutical sales (CZK m) and y-o-y change of Zentiva in the CEE countries analysed, 2008
149. Zentiva’s spending on research and development (CZK m), y-o-y change and its share as a proportion of the company’s net sales, 2003-2008

List of tables

1. Annual average exchange rates used for this report (euro to national currency unit), 2006-2008
2. Optimal drug prices in Ukraine, according to the doctors, 2009
3. Top 10 best selling drugs on the retail pharmaceutical market in Russia, generic and innovative, 2008
4. Top 10 best selling drugs in the reimbursement subdivision in Russia, generic and innovative, 2008
5. Top 10 best selling drugs on the hospital pharmaceutical market in Russia, generic and innovative, 2008
6. Top 10 best selling Rx drugs in Poland, generic and innovative, 2008
7. Top 10 best selling drug substances in the Czech Republic, generic and innovative, H1 2009
8. The most frequently reimbursed medicinal substances in the category of the cheapest medicines in the Czech Republic, Q2 2009
9. The best selling drugs in the category of the most expensive medicines in the Czech Republic, Q2 2009
10. Sales volume of selected best selling medicines in Romania (million units), generic and innovative, H1 2009
11. Top 10 best selling drugs in Romania, generic and innovative, H1 2009
12. Top 10 best selling drugs in Hungary, generic and innovative, 2008
13. Top 10 best selling drugs in Ukraine, generic and innovative, 2008
14. Comparison of drug patent expiry and data exclusivity periods (years) in the Central and Eastern European countries analysed, 2009
15. Examples of patent/trademark infringement cases in Central and Eastern Europe
16. Official retail margins for reimbursed drugs in Poland, 2009
17. Official margins for reimbursed drugs in the Czech Republic, 2009
18. Official wholesale margins for drugs in Romania, 2009
19. Official retail margins and gross margins for drugs in the Romania, 2009
20. Changes to reimbursement lists in Romania, July 2008
21. Solidarity fees paid by pharmacies in Hungary and their correlation with quarterly incomes from reimbursed drugs, 2009
22. Official wholesale markups for reimbursed drugs in Hungary, 2009
23. Official retail markups for reimbursed drugs in Hungary, 2009
24. Official wholesale and retail margins for Rx medicines in Slovakia, 2009
25. Comparison between July 2009 and October 2009 reimbursement lists in Slovakia, in terms of patient co-payment (%)
26. Comparison between July 2009 and October 2009 reimbursement lists in Slovakia, in terms of patient co-payment (€)
27. Official wholesale and retail margins for Rx drugs in Bulgaria, 2009
28. AstraZeneca sales in selected CEE countries, 2008
29. AstraZeneca selected best selling generic and innovative drugs in Russia (€‘000), retail, hospital and DLO, 2008 and H1 2009
30. AstraZeneca product pipeline development and clinical trials carried out in the CEE region, October 2009
31. Bayer sales in selected CEE countries, 2008
32. Bayer selected best selling generic and innovative drugs in Russia (€‘000), retail, hospital and DLO, 2008 and H1 2009
33. Patent expiry date of selected Bayer key original products in European Union countries, 2009
34. Bayer product pipeline development and clinical trials carried out in the CEE region, October 2009
35. GSK sales in selected CEE countries, 2008
36. GSK selected best selling generic and innovative drugs in Russia (€’000), retail, hospital and DLO, 2008 and H1 2009
37. Patent expiry date of selected GlaxoSmithKline key original products in European Union countries, 2009
38. Selected GSK clinical trials carried out in CEE countries, October 2009
39. Novartis sales in selected CEE countries, 2008
40. Novartis selected best selling generic and innovative drugs in Russia (€’000), retail, hospital and DLO, 2008 and H1 2009
41. Patent expiry date of selected Novartis key original products on major European markets, 2009
42. Novartis product pipeline development and clinical trials carried out in the CEE region, October 2009
43. Pfizer sales in selected CEE countries, 2008
44. Selected Pfizer clinical trials carried out in CEE countries, October 2009
45. Roche sales in selected CEE countries, 2008
46. Data exclusivity of selected Roche key original products in European Union countries, 2009
47. Roche product pipeline development and clinical trials carried out in the CEE region, October 2009
48. Sanofi-Aventis sales in selected CEE countries, 2008
49. Sanofi-Aventis selected best selling drugs in Russia, 2008
50. Patent expiry date of selected Sanofi-Aventis key original products in CEE countries, 2009
51. Sanofi-Aventis product pipeline development and clinical trials carried out in the CEE region, July 2009
52. Servier sales in selected CEE countries, 2008
53. Servier selected best selling generic and innovative drugs in Russia (€’000), retail, hospital and DLO, 2008 and H1 2009
54. Financial results of Balkanpharma member companies (BGN ‘000), 2007 and 2008
55. Selected drugs launched by Antibiotice in Romania, 2009
56. Dr. Reddy’s best selling products in Russia ($ m), 2006-2008
57. Dr. Reddy’s clinical trials carried out worldwide, March 2009
58. Drugs launched by Egis in Hungary, H1 2009
59. Generic and innovative drugs launched by Gedeon Richter in selected CEE countries analysed, 2008
60. Selected Gedeon Richter clinical trials, September 2009
61. Krka best selling drugs in the CEE countries analysed, H1 2009
62. Krka’s selected marketing authorisations gained via centralised procedure in the EU, 2009
63. Pharmstandard best selling generic and innovative drugs in Russia (RUB m), H1 2009
64. Pharmstandard innovative drugs brands, H1 2009
65. Teva innovative drug brands and patent expiry date, 2009
66. Teva generic drug brands in selected CEE countries, 2008
67. Teva clinical trials, September 2009
68. Zentiva top best selling brands (CZK m), 2008
69. Zentiva best selling generic drugs, new drugs launched and new marketing authorisations received on selected CEE markets, 2008
70. Top 10 leading companies on the Russian retail pharmaceutical market, by sales value, 2008
71. Top 10 leading companies on the Russian hospital market, by sales value, 2008
72. Top 10 leading companies on the Polish pharmaceutical market, by sales value, 2008
73. Selected leading innovative companies on the Czech pharmaceutical market, 2008
74. Top 10 leading companies on the Romanian pharmaceutical market, by sales value, 2008
75. Top 10 leading companies on the Hungarian pharmaceutical market, by sales value, 2008
76. Top 10 leading companies on the Romanian pharmaceutical market, by sales value, H1 2009
77. Top 10 leading foreign generic companies on the Ukrainian pharmaceutical market, by sales value, 2008
78. Top five leading innovative companies on the Ukrainian pharmaceutical market, by sales value, 2008
79. Top five leading companies on the Bulgarian pharmaceutical market, by sales volume, 2008